News

Cibus Advances Agricultural Innovation with New Herbicide Traits

Cibus Advances Agricultural Innovation with New Herbicide Traits

Cibus Gains Approval for Herbicide Tolerance Traits in Ecuador

In a notable development for agricultural technology, Cibus, Inc. (NASDAQ: CBUS), has received approval from the Ministry of Agriculture and Livestock in Ecuador for its innovative herbicide tolerance Rice traits (HT1 and HT3). This decision confirms that these advanced traits are on par with those developed through traditional breeding methods, allowing them to be governed by the same regulatory framework present in Ecuador's Organic Law of Agrobiodiversity.

Understanding Cibus' Rapid Trait Development System

The Rice varieties equipped with Cibus' traits utilize the company's advanced Rapid Trait Development System™ (RTDS). This technology signifies a breakthrough in the realm of plant genetics, facilitating targeted modifications without the incorporation of recombinant DNA—meaning that no foreign genetic material is introduced during the crops’ development stages. Cibus' HT1 and HT3 traits have now been cleared for registration and commercialization, effectively sidestepping stringent laws that normally restrict transgenic (GMO) crops.

Quotes and Insights from Cibus' Leadership

Dr. Peter Beetham, Co-Founder and Interim CEO of Cibus, expressed his satisfaction with the Ministry's decision, highlighting how it will empower Ecuadorian farmers. “With the right tools and technology, we can help growers tackle the intensifying challenges of climate change and enhance their productivity. The herbicide management solutions we've developed are vital to this effort,” he stated.

Furthermore, Fernando de la Puente, Corporate Vice President of Interoc, echoed the excitement for the approval. He noted, “This determination will accelerate our efforts to provide cutting-edge agricultural solutions that benefit growers in the Rice community.”

Strategic Partnerships and Future Plans

Cibus plans to expand the footprint of its herbicide tolerance traits throughout Latin America through a strategic partnership with Interoc, an established player in Rice seed genetics. Their alliance promises the integration of Cibus' advanced traits into elite Rice lines, enhancing effective weed management solutions across the region.

Martin Poveda, Senior Director of Rice and Business Affairs at Cibus, emphasized the scope of their ambitions. “With this regulatory clearance in Ecuador, we look forward to collaborating with Interoc to further cultivate HT1 and HT3 varieties. Our goal is to extend the benefits offered by our RTDS breeding platform to vital food and feed crops across Latin America,” he commented.

Looking Ahead: Expansion Beyond Ecuador

This breakthrough in Ecuador holds the promise of regulatory approval in additional key markets within Latin America. Cibus is optimistic that this development will set a precedent, facilitating the acceptance of its herbicide tolerance traits in other countries, thus broadening their market impact.

About Cibus

Cibus is recognized for its pioneering gene editing technologies aimed at enhancing agricultural productivity. By addressing significant challenges like pest and disease management, which the United Nations estimates incur global economic losses nearing $300 billion annually, Cibus positions itself as a critical partner for farmers. The company focuses not on seed production but on providing technology to other seed companies through licensing agreements in exchange for royalties on seed sales.

With a strategic focus on key crops such as canola, rice, and soybean, Cibus leverages high-throughput gene editing technology to expedite the development and commercialization of crucial plant traits. Their ongoing innovations reflect a commitment to deliver effective solutions to modern agricultural challenges.

Frequently Asked Questions

What is Cibus' recent achievement in Ecuador?

Cibus has gained approval for its herbicide tolerance Rice traits (HT1 and HT3), equating them with conventional breeding methods and allowing commercial registration.

What technology does Cibus employ for its trait development?

Cibus uses its Rapid Trait Development System (RTDS), which allows for targeted genetic changes without using recombinant DNA.

How will this approval benefit farmers?

The approval will equip farmers in Ecuador with improved weed management solutions, potentially increasing their productivity amid shifting agricultural challenges.

Who is Interoc and what role do they play?

Interoc is a key partner for Cibus in expanding its herbicide tolerance traits throughout Latin America, integrating Cibus’ technologies into their Rice seed offerings.

What are Cibus' long-term goals?

Cibus aims to enhance agricultural productivity and develop innovative traits for major global crops using its gene editing technologies, thereby supporting farmers in their productivity efforts.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 21

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 6

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 7

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 6

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading

Top 5 Most Recently Viewed Articles

AIP Realty Trust Announces Successful Non-Brokered Offering

Updated Category News Views 177

AIP Realty Trust's Financial Milestone Achieved AIP Realty Trust has made waves in the investment community by successfully finalizing the initial tranche of a significant non-brokered private placement. These efforts have brought in an impressive total of 7,260,000 Preferred Units—Series B Convertible, valued at US$0.50 each, resulting in gross proceeds of...

Continue Reading
Medtronic's BrainSense™ Receives CE Marking for Parkinson's Care

Updated Category News Views 499

Medtronic’s Innovative Approval for Parkinson's Treatment Medtronic plc (NYSE: MDT), a global leader in healthcare technologies, has achieved a significant milestone by receiving CE Mark approval for its BrainSense™ Adaptive deep brain stimulation (aDBS) system and the BrainSense™ Electrode Identifier (EI). This remarkable advancement introduces the world's first...

Continue Reading
Understanding the New Rating for abrdn Asia-Pacific Income Fund

Updated Category News Views 84

KBRA's Rating Insights on abrdn Asia-Pacific Income Fund Recently, KBRA has taken significant steps by assigning a new rating to the Series B Mandatory Redeemable Preferred Shares (MRPS) of abrdn Asia-Pacific Income Fund, Inc. (NYSE: FAX). This rating stands at 'AA-', illustrating the organization's confidence in the stability and security of these investment instruments....

Continue Reading
Protect Your Investment: Join the Applied Therapeutics Class Action

Updated Category News Views 156

Understanding the Class Action for Applied Therapeutics Investors As an investor in Applied Therapeutics, Inc. (APLT), you may have felt the financial impact of recent challenges the company has encountered. The firm is currently facing a class action lawsuit aimed at addressing securities fraud that adversely affected investors between specific dates. This situation is...

Continue Reading
Heritage Capital Group Facilitates Mittauer's Strategic Sale

Updated Category News Views 205

Heritage Capital Group Facilitates Mittauer's Strategic Sale Heritage Capital Group, Inc. ("Heritage"), a respected investment banking and financial advisory firm known for serving middle-market and emerging growth companies, has successfully guided its client, Mittauer & Associates, Inc. ("Mittauer"), through a significant transition in its business landscape. This...

Continue Reading